drugset / Trial / NCT06409104
Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing ERCP
RandomizedParallel-groupDouble-blindSupportive care
Summary
The aim of this study is to compare the efficacy and safety of propofol and dexmedetomidine during ERCP regarding hemodynamic, respiratory, sedative and cognitive functions.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2024-01-01
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.2 ug/kg | — |
| Comparator | Dexmedetomidine | Other / unclassified | 0.7 ug/kg | — |
| Comparator | Propofol | Small molecule | 0.05 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 0.1 mg/kg | Intravenous |
Indications
No indication recorded.